~~<i id='A8146A0BDB'><strike id='A8146A0BDB'><tt id='A8146A0BDB'><pre id='A8146A0BDB'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：explore 2025-10-04 09:22:05 Page View：2712

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Gene therapies for deafness raise the question: Do deaf people want a 'cure'?
Next article： Malaria cases in Florida and Texas: Here’s what you need to know

explore

Duchenne breakthrough therapy leaves behind pioneering families

DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

Dark money group runs ads on China biotech bill

BGIGrouphasbeentargetedbyadarkmoneygroupsupportingtheBIOSECUREAct.STR/AFPviaGettyImagesYou’rereading

Medical leaders decry Supreme Court decision on affirmative action

STEFANIREYNOLDS/AFPviaGettyImagesMedicalleadersonThursdayreactedswiftlytotheSupremeCourt’sdecisionto

Akili, maker of video game for ADHD, to be acquired for 34 million

AdobeAmonthafterannouncingitwasseekingstrategicalternatives,AkiliInteractive,makerofavideogamedesign